目的 本文主要对贝伐单抗在结直肠癌治疗中的安全性进行研究,以期为临床应用提供一定的指导.方法 回顾性分析使用贝伐单抗治疗的72例晚期结直肠癌病例.统计贝伐单抗不良反应发生率,通过单变量和多变量分析以确定贝伐单抗不良反应的潜在危险因素.结果 共有72例患者可进行安全性评价.最常见的药物不良反应是高血压(12.5%),出血(12.5%)和蛋白尿(8.3%).严重药物不良反应的发生率较低:出血的发生率为1.4%,静脉血栓栓塞事件发生率为1.4%,胃肠穿孔发生率为1.4%.通过多变量分析确定出了药物各种不良反应的高危因素.结论 贝伐单抗严重不良事件发生率较低,患有晚期或转移性结直肠癌的患者应用贝伐单抗安全性较好,患者的耐受性良好.%Objective To study the safety of bevacizumab in the treatment of colorectal cancer,in order to provide some guidance for the clinical application.Methods A retrospective analysis of 72 patients with advanced colorectal cancer who were admitted to our hospital and treated with bevacizumab was conducteol.Adverse reactions and incidence of bevacizumab were col-lected.A single variable and multivariate analysis was used to determine the potential risk factors for the adverse reactions of bev-acizumab.Results A total of 72 patients were evaluable for safety.The most common adverse drug reactions were hypertension (12.5%),hemorrhage(12.5%),and proteinuria(8.3%).The incidence of serious adverse drug reactions was low: the inci-dence of bleeding was 1.4 %,the incidence of venous thromboembolism was 1.4 %,and the incidence of gastrointestinal perfora-tion was 1.4 %.The high risk factors of adverse drug reactions were identified by multivariate analysis.Conclusion Bevacizumab has a low incidence of serious adverse events.Patients with advanced or metastatic colorectal cancer have better safety and better tolerance to bevacizumab.
展开▼
